Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 12Recruiting 6Unknown 3Terminated 3Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 17Breast 13Thoracic 7Genitourinary 7Head & Neck 4CNS 4Sarcoma 3Endocrine 2Dermatologic 2Tumor-Agnostic 1NET 1Gynecologic 1

Conditions

Melanoma 2

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Surgical Procedures, Operative × Dermatologic × Clear all
NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
60 enrolled
Dermatologic

Melanoma

NCT02938299 2024-09-19

Pivotal

Philogen S.p.A.

Phase 3 Active not recruiting
214 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡